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Abstract
BACKGROUND: Coronary atherosclerosis begins early in
life, but acute coronary syndromes in adults aged <30 years
are exceptional. We aimed to investigate the rate of occur-
rence, clinical and angiographic characteristics, and long-
term clinical outcome of acute coronary syndrome (ACS)
in young patients who were referred to two Swiss hospitals.
METHODS: From 1994 to 2010, data on all patients with
ACS aged <30 years were retrospectively retrieved from
our database and the patients were contacted by phone
or physician’s visit. Baseline, lesion and procedural char-
acteristics, and clinical outcome were compared between
patients in whom an underlying atypical aetiology was
found (non-ATS group; ATS: atherosclerosis) and patients
in whom no such aetiology was detected (ATS group). The
clinical endpoint was freedom from any major adverse car-
diac event (MACE) during follow-up.
RESULTS: A total of 27 young patients with ACS aged
<30 years were admitted during the study period. They ac-
counted for 0.05% of all coronary angiograms performed.
Mean patient age was 26.8 ± 3.5 years and 22 patients
(81%) were men. Current smoking (81%) and dyslipid-
aemia (59%) were the most frequent risk factors. Typical
chest pain (n = 23; 85%) and ST-segment elevation
myocardial infarction (STEMI; n = 18 [67%]) were most
often found. The ATS group consisted of 17 patients (63%)
Abbreviations
ACS acute coronary syndrome
ATS atherosclerosis
CABG coronary artery bypass graft surgery
CAD coronary artery disease
CD cardiac death
IQR interquartile range
MACE major adverse cardiac event
MI myocardial infarction
PCI percutaneous coronary intervention
STEMI ST-elevation myocardial infarction
TLR target lesion revascularisation
TVR target vessel revascularisation
and the non-ATS group of 10 patients (37%). Hereditary
thrombophilia was the most frequently encountered atypic-
al aetiology (n = 4; 15%). At 5 years, mortality and MACE
rate were 7% and 19%, respectively.
CONCLUSION: ACS in young patients is an uncommon
condition with a variety of possible aetiologies and distinct
risk factors. In-hospital and 5-year clinical outcome is sat-
isfactory.
Keywords: acute coronary syndrome; percutaneous
coronary intervention; young patients
Background
Acute coronary syndrome (ACS) is rarely encountered in
young adults and may have unusual causes. Data on incid-
ence, risk factors and clinical outcome of ACS in this par-
ticular subset are limited. On currently available eviden-
ce, young patients represent 0.4%–19% of all ACS cases,
depending on the cut-off age used [1–13]. Most studies
define young patients as aged less than 45 years. Alioglu
et al. found that, in 2,400 patients suffering from ACS, 2%
of patients were aged <35 years [12]. One study reported
that 0.4% of patients with ACS were aged <30 years [13].
As classic coronary atherosclerotic plaque rupture is con-
sidered to be rare during the early decades of life, uncom-
mon aetiologies may be considered. In line with this, cardi-
ovascular risk factors, the extent of coronary artery disease
and clinical outcome after ACS might be different from
those of older patients [14–20].
Therefore, we investigated the incidence, baseline charac-
teristics and long-term clinical outcome of ACS in patients
younger than 30 years who were referred to our institu-
tions. We also sought to compare the aforementioned vari-
ables between patients in whom an underlying atypical ae-
tiology was found and patients in whom no such aetiology
was detected.
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Methods
Study population and data collection
From 1994 to 2010, data for all patients with ACS aged
<30 years who had been admitted to two Swiss hospitals
(University Hospital Bern and Hospital Fribourg) were ret-
rospectively retrieved from our database. This was a pro-
spective longitudinal study. All patients were identified
in the catheter laboratory databases and prospectively fol-
lowed up. Inclusion criteria were age ≥18 years and ≤30
years at the time of ACS, diagnosis of ACS in accordance
with the consensus paper from the ESC-ACC-AHA-WHF
joint taskforce [21], willingness to provide informed con-
sent and to participate in follow-up (ESC: European Soci-
ety of Cardiology; ACC: American College of Cardiology;
AHA: American Heart Association; WHF: World Heart
Federation). Patients <18 or >30 years of age and those un-
able or unwilling to provide informed consent or to par-
ticipate in follow-up were excluded from the study. The
study complied with the Declaration of Helsinki regarding
investigations in humans and was approved by the Institu-
tional Ethics Committee.
Medical records reviewed included prehospitalisation and
paediatric medical history, drug abuse, physical examina-
tion, homocysteinaemia, antiphospholipid antibody titre,
other thrombophilic conditions, blood lipids, coronary an-
giography and ventriculography, 12-lead electrocardiogram
(ECG), percutaneous coronary intervention (PCI) or coron-
ary artery graft bypass surgery (CABG) reports, as well
as postprocedural echocardiography. Dyslipidaemia was
defined in accordance with the reports of the National Cho-
lesterol Education Programme (Adult Treatment Panels II
and III) [22, 23]. Hyperhomocysteinaemia was considered
present when plasma concentrations were >15 µmol/l.
Quantitative coronary angiographic analysis
Coronary angiograms were recorded at baseline and im-
mediately after the intervention. Digital angiograms were
analysed at the angiographic core laboratory at Bern
University Hospital, Switzerland, with the use of an auto-
mated edge-detection system using the CMS-GFT al-
gorithm (MEDIS™, Leiden, The Netherlands). Quantitat-
ive measurements included the diameter of the reference
vessel, minimum luminal diameter and percentile diameter
of the stenosis (defined as the diameter of the reference
vessel minus the minimal luminal diameter, divided by the
reference diameter and multiplied by 100).
Follow-up
Patients were followed up for up to 15 years (range 0.1–15
years). Information regarding clinical status was collected at
clinic visits or by means of telephone interview and was ob-
tained 1, 2 and 5 years after the ACS that had led to study in-
clusion. All patients were contacted finally by telephone pri-
or to data analysis. When the patient was not accessible, data
were retrieved from the referring physician, hospital elec-
tronic database or Municipal Civil Registries. The clinical
endpoint was freedom from any major adverse cardiac event
(MACE) during follow-up. MACE was defined as the oc-
currence of cardiac death (CD), nonfatal myocardial infarc-
tion (MI), or target vessel revascularisation (TVR) during
the follow-up period. Target lesion revascularisation (TLR)
was defined as any repeat percutaneous or surgical interven-
tion, or other complication of the target lesion. The target le-
sion was defined as the treated segment from 5 mm proxim-
al to the stent to 5 mm distal to the stent. TVR was defined as
any repeat PCI of any segment of the target vessel, defined
as the entire major coronary vessel proximal and distal to the
target lesion, including upstream and downstream branches
and the target lesion itself. Any death due to a proximate car-
diac cause, all unwitnessed deaths and deaths of unknown
causes were considered cardiac. Definite, probable and pos-
sible stent thromboses were determined in accordance with
the Academic Research Consortium (ARC) definitions [24].
Stent thrombosis was defined as early, late or very late if the
event occurred within 30 days, <1 year or >1 year, respect-
ively, after the procedure.
Statistical analysis
Statistical analysis was performed using SPSS software
18.0 (SPSS Inc., Chicago, IL, USA). Statistical analysis
was primarily descriptive and focused on reporting the in-
cidence of risk factors, clinical presentation, the revascu-
larisation strategy employed and the outcome. Continuous
variables are presented as mean ± standard deviation or me-
dian with interquartile range (IQR). Categorical variables
are presented as counts and percentages.
In a univariate analysis, baseline, lesion and procedural
characteristics as well as clinical outcome were compared
between patients with and without an underlying atypical
aetiology. For continuous variables the parametric t-test or
the nonparametric Mann-Whitney U test were employed
according to their distribution. Contingency tables were
created for categorical variables and the chi-square and the
Fisher’s exact test were used to account for differences.
Results
Baseline characteristics
A total of 27 young patients with ACS aged <30 years were
admitted during the study period, and accounted for 0.05%
Figure 1A
Cumulative survival in patients <30 years presenting with acute
coronary syndrome.
ATS = atherosclerosis; non-ATS = patients without angiographic
evidence of atherosclerosis.
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of all coronary angiographies performed at our institutions
during this period. Baseline clinical and procedural charac-
teristics are summarised in table 1. Mean patient age was
26.8 ± 3.5 years and 22 patients (81%) were men. Current
smoking (81%), dyslipidaemia (59%) and positive family
history (44%) were the most frequently encountered risk
factors.
At presentation, typical chest pain occurred in 23 patients
(85%), syncope in 3 patients (11%) and isolated dyspnoea
in 2 patients (7%). ST-elevation myocardial infarction
(STEMI) was present in 18 patients (67%) and cardiogenic
shock in 2 patients (7%). Initial mean left ventricular ejec-
tion fraction was 48% ± 11%.
Coronary angiography was performed in all patients.
Single vessel disease was found in 19 patients (70%) and
the left anterior descending artery was involved in 22 cases
(81%). Mean stenosis was 91% ± 22%. PCI was performed
in 19 patients (70%), of whom 15 (56%) were stented.
Table 2 shows further lesion and procedural characteristics.
Underlying aetiology
ACS was due to an unusual condition in ten patients (37%,
nonatherosclerosis [non-ATS] group): hereditary thrombo-
philia with or without patent foramen ovale in four patients
(15%), cocaine abuse in two (7%), Kawasaki and familial
Mediterranean fever in two (7%), emboli in infective en-
docarditis in one (4%), and antiphospholipid antibody syn-
drome in one (4%). None of the eight patients with plasma
homocysteine measurements (10.5 ± 2.2 µmol/l) had val-
ues that were above the homocysteinaemia cut-off value
(15 µmol/l).
In the remaining 17 patients (63%), atherosclerosis was
present (ATS group). In these patients, 75% had at least
two classical risk factors for coronary artery disease (me-
dian 2, IQR 2‒3) whereas patients with an unusual con-
dition presented these risk factors less frequently (median
1.5, IQR 1‒3; p = 0.34).
No statistically significant difference regarding risk factors,
or clinical or angiographic presentation between patients
with or without an uncommon condition could be detected.
Figure 1B
Cumulative survival free of major cardiac adverse events (MACE)
in patients <30 years presenting with acute coronary syndrome.
ATS = atherosclerosis; non-ATS = patients without angiographic
evidence of atherosclerosis.
Clinical outcome
In-hospital MACE occurred in two patients (7%): One pa-
tient died and another had nonfatal MI as a result of early
definite stent thrombosis (one acute; one subacute).
Of the 26 initial survivors, one patient was lost during
follow-up. Median follow-up duration was 5.1 years (IQR
2.6–9.6 years). Table 3 indicates in-hospital and 5-year out-
comes. Figure 1 depicts the Kaplan-Meier curve for 5-year
survival (1A) and survival free of MACE (1B). Overall, the
MACE rate was found to be 19% at 5 years follow-up. Two
patients (7%) died within the 5 years succeeding the ACS
that had led to study inclusion.
Discussion
ACS in patients under the age of 30 is a rare entity. We
present the largest series reported to date. Our findings
are as follows. Firstly, at least one in three patients suffer
from an atypical underlying condition of which hereditary
thrombophilia is the most common. Secondly, early arthro-
sclerosis is more frequently encountered in this population
than we suspected. Of these patients, approximately three
of four will have at least two classical risk factors for the
development of CAD. Thirdly, this part of the population
is prone to present with single vessel disease – especially
in the left anterior descending coronary artery. Finally, in-
hospital outcome is acceptable and was darkened solely
by procedure-related complications, specifically early stent
thrombosis.
With regard to risk factors, the high prevalence of smoking
in this particular patient subset is of particular interest. Our
findings are in line with a previously reported prevalence of
77% in Swiss patients aged ≤35 years by Schoenenberger
and colleagues [25]. Smoking is the most crucial risk factor
for the development of ACS in this part of the population.
The literature reports smoking by up to 82% of young pa-
tients suffering from ACS [7, 26]. Case-control studies in-
dicate that smoking is an independent risk factor for the
development of ischaemic heart disease in young patients
[27]. An interesting finding is reported by Huang and col-
leagues who found that the rate of smoking in patients aged
≤35 years and suffering from MI was significantly high-
er than in patients >65 years old suffering from the same
condition.[28] Smoking persistence is associated with the
occurrence of secondary events after MI in young patients
[29]. Taken together, these data underline the importance of
primary and secondary prevention specifically in this sub-
set of patients.
At 5 years, around 90% of the patients were alive and
around 80% were free from any MACE. This satisfactory
long-term outcome has already been suggested previously.
Possible explanations are the lesser extent of CAD in com-
parison with older patients, more preserved left ventricular
function, and a higher ability of young patients to modify
their lifestyle. In line with this, Ralldis and colleagues
showed that decreased left ventricular ejection fraction at
presentation and the continuation of smoking after myocar-
dial infarction were most predictive for further MACEs in
young patients [29].
Regarding the incidence of stent thrombosis, young age is
usually considered to be protective. On the one hand, one
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might assume that since adverse events are rare in this pop-
ulation such procedure-related complications become more
evident. On the other hand, patient compliance was not as-
sessed in the present study and might affect this finding.
Table 1: Baseline characteristics and clinical presentation on admission.
Overall (n = 27) Non-ATS (n = 10) ATS (n = 17) p-value
Baseline characteristics
Age in years, mean ± SD 26.8 ± 3.5 27.1 ± 3.8 26.6 ± 3.5 0.96
Male, n (%) 22 (81) 7 (70) 15 (88) 0.33
Dyslipidaemia, n (%) 16 (59) 6 (60) 10 (59) 1
Hypertension, n (%) 4 (15) 1 (10) 3 (18) 1
Smoking, n (%) 22 (81) 8 (80) 15 (82) 0.63
Family history, n (%) 12 (44) 3 (30) 9 (53) 0.25
Cumulative RF, median (IQR) 2 (1–3) 1.5 (1–3) 2 (2–3) 0.34
Previous MI, n (%) 3 (11) 2 (20) 1 (6) 0.56
Previous PCI, n (%) 3 (11) 2 (20) 1 (6) 0.56
Clinical presentation
Chest pain, n (%) 23 (85) 10 (100) 13 (76) 0.5
Shortness of breath, n (%) 2 (7) 2 (20) 0 (0) 0.16
Syncope, n (%) 3 (11) 0 (0) 3 (18) 0.25
Ventricular fibrillation, n (%) 2 (7) 0 (0) 2 (12) 0.5
STEMI, n (%) 18 (67) 6 (60) 11 (65) 0.69
Pain to needle time in hours median (IQR) 10 (3–36) 4 (1–31) 26 (6–38) 0.16
NSTEMI, n (%) 6 (22) 2 (20) 4 (24) 1
Cardiogenic shock, n (%) 2 (7) 0 (0) 2 (12) 0.53
LVEF as percentage, mean ± SD 48 ± 11 41 ± 13 53 ± 7 0.02
Stenosis as percentage, mean ± SD 91 ± 22 96 ± 8 88 ± 26 0.36
ATS = atherosclerosis; IQR = interquartile range; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NSTEMI = non ST-elevation myocardial infarction: PCI
= percutaneous coronary intervention; RF = risk factor; SD = standard deviation, STEMI = ST-elevation myocardial infarction
Table 2: Lesion and procedural characteristics.
Overall (n = 27) Non-ATS (n = 10) ATS (n = 17) p-value
LAD, n (%) 22 (81) 9 (90) 13 (76) 0.62
LCX, n (%) 7 (26) 1 (10) 6 (35) 0.2
RCA, n (%) 9 (33) 1 (10) 8 (47) 0.09
Intermediate, n (%) 1 (4) 1 (10) 0 (0) 0.37
Single vessel, n (%) 20 (70) 9 (90) 10 (59) 0.19
Multivessel, n (%) 8 (30) 1 (10) 7 (41) 0.19
PCI, n (%) 19 (70) 6 (60) 13 (77) 0.42
Stent, n (%) 15 (56) 4 (40) 11 (65) 0.26
BMS, n (%) 6 (22) 2 (20) 4 (24) 1
DES, n (%) 8 (30) 2 (20) 6 (35) 0.67
POBA, n (%) 6 (19) 3 (30) 2 (12) 0.33
Thrombolysis, n (%) 4 (15) 1 (10) 3 (18) 1
CABG, n (%) 5 (19) 2 (20) 3 (18) 1
ATS = atherosclerosis; BMS = bare metal stent; CABG = coronary artery bypass graft surgery; DES = drug-eluting stent; LAD = left anterior descending artery; LCX =
circumflex artery; POBA = plain old balloon angioplasty; RCA: right coronary artery
Table 3: In-hospital and 5-year outcomes.
Overall (n = 27) Non-ATS (n = 10) ATS (n = 17) p-value
In-hospital MACE, n (%) 2 (7) 0 (0) 2 (12) 0.52
In-hospital death, n (%) 1 (4) 0 (0) 1 (6) 1
In-hospital cardiac death, n (%) 1 (4) 0 (0) 1 (6) 1
In-hospital MI, n (%) 2 (7) 0 (0) 2 (12) 0.52
In-hospital stent thrombosis, n (%) 2 (7) 0 (0) 2 (12) 0.52
5-year MACE, n (%) 5 (19) 1 (10) 4 (24) 0.62
5-year death, n (%) 2 (7) 0 (0) 2 (12) 0.52
5-year cardiac death, n (%) 2 (7) 0 (0) 2 (12) 0.52
5-year MI, n (%) 2 (7) 0 (0) 2 (12) 0.52
5-year TLR, n (%) 2 (7) 0 (0) 2 (12) 0.52
5-year TVR, n (%) 3 (11) 1 (10) 2 (12) 1
5-year revascularisation, n (%) 3 (11) 1 (10) 2 (12) 1
5-year stent thrombosis, n (%) 2 (7) 0 (0) 2 (12) 0.52
ATS = atherosclerosis; MI = acute myocardial infarction; MACE = major adverse cardiac events; TLR = target lesion revascularisation; TVR: target vessel
revascularisation; ST: stent thrombosis
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The main limitation of this study is the small number of
patients. Although we neither performed an a priori nor
an a posteriori sample size calculation, statistical power
is likely to be low. External validity is threatened by the
lack of statistical significance with regard to type II errors
for the endpoints. However, the results of the present study
could help determine the sample size for further research.
As some of the data collection was retrospective our study
could be subject to recall or information bias. Generalisa-
tions must therefore be made with caution.
Conclusion
ACS in young patients is an uncommon condition with a
variety of possible aetiologies and distinct risk factors. The
latter should be vigorously controlled – especially in pa-
tients with a positive family history of premature CAD. In-
hospital and 5-year clinical outcome is acceptable. Further
research is needed to corroborate the findings of the present
study.
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Figures (large format)
Figure 1A
Cumulative survival in patients <30 years presenting with acute coronary syndrome.
ATS = atherosclerosis; non-ATS = patients without angiographic evidence of atherosclerosis.
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Figure 1B
Cumulative survival free of major cardiac adverse events (MACE) in patients <30 years presenting with acute coronary syndrome.
ATS = atherosclerosis; non-ATS = patients without angiographic evidence of atherosclerosis.
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